Breast Cancer Market - Global Industry Analysis, Size and Growth, 2023

Cancer is a disease characterized by uncontrolled growth of cell. There are about 100 different types of cancer and each is classified by the type of cell where it occurs and affects. Breast cancer is mostly prevalent in women, however, breast cancer in men is rare. It is frequently diagnosed in aged women and one of the leading causes of death among them. Some of the most common types of breast cancer are ductal carcinoma in situ (DCIS), lobular carcinoma and invasive ductal carcinoma.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/-breast-cancer-market/report-sample

DCIS, also known as intraductal carcinoma, begins in the lining of the milk ducts. Milk ducts are thin tubes carrying milk from lobules of the breast to the nipple. Lobule carcinoma originates in the lobules or milk glands of the breast. Invasive ductal carcinoma is the most common type of breast cancer. It starts in a milk duct of the breast, ruptures through the wall of the duct and grows into the fatty tissue of the breast. It spreads to other parts of body through bloodstream.

The global breast cancer market covers various diagnostic technologies and therapeutic drugs. Diagnostic segment is further sub-segmented into various tests which are used to diagnose breast cancer. Some of the major diagnostic tests are biopsy, mammography, MRI, etc. Therapeutic segment covers hormone therapies and chemotherapy drugs. Some of the major drugs are Trastuzumab, Bevacizumab, Anastrozole, Capecitabine, Carboplatin, Denosumab, Docetaxel, Doxorubicin, Eribulin, Exemestane, Fluorouracil, Fulvestrant, Gemcitabine, Ixabepilone, Lapatinib, Letrozole, Methotrexate, Paclitaxel and Tamoxifen.

For more information visit: https://www.psmarketresearch.com/market-analysis/-breast-cancer-market

Some of the major competitors in the market are Astrazeneca PLC, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Novartis AG, Sanofi-Aventis. Pfizer, Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd.